On Mar. 4, 2021, Soligenix announced publication of pre-clinical immunogenicity studies for CiVaxﾙ (heat stable COVID-19 vaccine program) demonstrating rapid-onset, broad-spectrum, neutralizing antibody and cell-mediated immunity is confirmed using full-length Spike protein antigens. The article was posted as an accelerated preprint on bioRxiv. The work continued under a $1.5 million Small Business Innovation Research (SBIR) grant awarded to Soligenix in December 2020.